Lateral Flow Assays Market Intelligence: Size, Share and Growth Outlook Through 2036
By Product, Application, and Technique — Global Forecast to 2036
By Brevintel Editor•June 2026•PDF + Excel
Market Size (2025)
$4.7B
Market Forecast (2036)
$7.7B
CAGR (2025-2036)
4.6%
The lateral flow assays market was valued at USD 4.7 billion in 2025. The market is set to reach USD 4.9 billion by 2026-end and grow at a CAGR of 4.6% between 2026-2036 to reach USD 7.7 billion by 2036. Kits and Reagents will dominate with a 72.0% share, while Clinical Testing will lead with a 46.0% share. Japan is projected to be the fastest-growing market at 4.6%, followed by the USA at 4.5%. Incremental opportunity of USD 2.8 Bn between 2026 and 2036 reflects clinical adoption and regulatory compliance cycles. Abbott Laboratories and F. Hoffmann-La Roche Ltd lead the competitive field.
Key Market Trends & Insights
The lateral flow assays market was valued at USD 4.7 billion in 2025 and is set to reach USD 4.9 billion by 2026-end.
The market is forecast to grow at a CAGR of 4.6% between 2026-2036 to reach USD 7.7 billion by 2036.
Kits and Reagents will dominate with a 72.0% share, while Clinical Testing will lead with a 46.0% share.
Japan is projected to be the fastest-growing market at 4.6%, followed by the USA at 4.5%.
This USD 2.8 Bn incremental opportunity between 2026 and 2036 is a function of clinical adoption, regulatory compliance cycles, and geographic expansion of procurement.
Lateral Flow Readers are expected to witness steady adoption as demand grows for quantitative and digitally connected diagnostic testing solutions.
Sandwich Assays remain the most common processing approach, with competitive assays gaining popularity for specific applications.
Market Overview
Market Size and Outlook
The lateral flow assays market was valued at USD 4.7 billion in 2025 and is set to reach USD 4.9 billion by 2026-end.
The market is set to grow at a CAGR of 4.6% between 2026-2036 to reach USD 7.7 billion by 2036.
The lateral flow assays market is valued at USD 4.9 Bn in 2026 and is predicted to reach USD 7.7 Bn by 2036, growing at a CAGR of 4.6%.
Kits and Reagents will dominate with a 72.0% share, while Clinical Testing will lead with a 46.0% share.
This USD 2.8 Bn incremental opportunity between 2026 and 2036 is a function of the cumulative impact of clinical adoption, regulatory compliance cycles, and the geographic expansion of procurement.
Demand and Growth Drivers
Clinical Testing, and Veterinary Diagnostics applications are expected to sustain procurement of kits and reagents products as clinical protocols tighten and patient populations expand through 2036.
Sandwich Assays and competitive assays are projected to shape procurement patterns, with regulatory-approved formats capturing the largest volume share.
Kits and Reagents is expected to account for 72.0% of the product segment in 2026, supported by demand across Test Kits, Infectious Disease Test Kits, and Pregnancy and Fertility Test Kits.
Analyst Perspective
Brevintel analysis indicates companies that can align kits and reagents product portfolios with evolving clinical testing requirements while maintaining cost-competitive pricing across lateral flow readers categories are expected to strengthen procurement positions.
Abbott Laboratories and F. Hoffmann-La Roche Ltd lead through regulatory approval breadth, clinical evidence portfolios, and institutional procurement contracts.
Market Dynamics
Drivers, Restraints, and Opportunities
Growth is credited to increasing demand for Kits and Reagents, and Lateral Flow Readers in Clinical Testing, Veterinary Diagnostics, and Food Safety and Environmental Testing applications.
Lateral Flow Readers is a secondary growth category, with Portable Readers and Handheld Devices gaining traction as procurement diversifies.
Replacement and compliance cycles sustain demand in North America and Western Europe.
Segmentation Analysis
Product Outlook
Kits and Reagents is expected to account for 72.0% of market revenue in 2026 owing to its widespread use across infectious disease, pregnancy, and fertility testing applications.
Lateral Flow Readers are expected to witness steady adoption as demand grows for quantitative and digitally connected diagnostic testing solutions.
Application and Technique Outlook
Clinical Testing accounts for 46.0% of application demand due to its extensive use in infectious disease detection, pregnancy testing, and point-of-care diagnostics.
The most common processing approach is Sandwich Assays, however competitive assays are gaining popularity for specific applications.
Regional Outlook
Japan and USA
Japan is projected to lead growth at 4.6% through 2036, driven by PMDA approval pathways, aging population demographics, and hospital automation investment supporting kits and reagents demand.
USA at 4.5% reflects FDA regulatory pathway maturity, Medicare reimbursement structures, and high per-capita kits and reagents utilization rates in hospital and ambulatory settings.
Competitive Landscape
Overview
Abbott Laboratories and F. Hoffmann-La Roche Ltd lead the competitive field through regulatory approval breadth, clinical evidence portfolios, and institutional procurement contracts.
BD (Becton, Dickinson and Company), Bio-Rad Laboratories, Inc., QuidelOrtho, and OraSure Technologies compete across infectious disease and point-of-care formats.
Biosynex (Chembio Diagnostics), Roche Diagnostics (LumiraDx point-of-care technology), and DCN Dx compete in specialty and reader-connected formats.
